Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their Introduction
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25168949 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Paweł Tyrna und 3 weiteren Autor:innen. Beteiligte Einrichtung: Histology and Embryology Students' Science Association, Department of Histology and Embryology, Faculty of Medicine, Warsaw Medical University, Chalu…. Hauptthemen laut MEDLINE: Proteasome Inhibitors, Drug Resistance, Neoplasm, Multiple Myeloma. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Proteasome inhibitors (PIs), bortezomib, carfilzomib, and ixazomib, are the first-line treatment for multiple myeloma (MM). They inhibit cytosolic protein degradation in cells, which leads to the accumulation of misfolded and malfunctioned proteins in the cytosol and endoplasmic reticulum, resulting in cell death. Despite being a breakthrough in MM therapy, malignant cells develop resistance to PIs via different mechanisms. Understanding these mechanisms drives research toward new anticancer agents to overcome PI resistance. In this review, we summarize the mechanism of action of PIs and how MM cells adapt to these drugs to develop resistance. Finally, we explore these mechanisms to present strategies to interfere with PI resistance. The strategies include new inhibitors of the ubiquitin–proteasome system, drug efflux inhibitors, autophagy disruption, targeting stress response mechanisms, affecting survival and cell cycle regulators, bone marrow microenvironment modulation, and immunotherapy. We list potential pharmacological targets examined in in vitro, in vivo, and clinical studies. Some of these strategies have already provided clinicians with new anti-MM medications, such as panobinostat and selinexor. We hope that further exploration of the subject will broaden the range of therapeutic options and improve patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Histology and Embryology Students' Science Association, Department of Histology and Embryology, Faculty of Medicine, Warsaw Medical University, Chalubinskiego 5, 02-004 Warsaw, Poland.
- 1st Chair and Department of Cardiology, Medical University of Warsaw, Banacha 1A, 02-097 Warsaw, Poland.
- Department of Organic and Physical Chemistry, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1 Str., 02-093 Warsaw, Poland.
- Department of Histology and Embryology, Faculty of Medicine, Warsaw Medical University, Chalubinskiego 5, 02-004 Warsaw, Poland.
ORCID-Profile: Paweł Tyrna, Grzegorz Procyk, Łukasz Szeleszczuk, Izabela Młynarczuk-Biały
Zitieren
APA
Tyrna, P., Procyk, G., Szeleszczuk, Ł., & Młynarczuk-Biały, I. (2024). Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their Introduction. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25168949
Vancouver
Tyrna P, Procyk G, Szeleszczuk Ł, Młynarczuk-Biały I. Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their Introduction. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25168949
BibTeX
@article{Tyrna2024,
author = {Tyrna, Paweł and Procyk, Grzegorz and Szeleszczuk, Łukasz and Młynarczuk-Biały, Izabela},
title = {Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their Introduction},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25168949}
}
EUVIMED